Form 4: REGENXBIO Director Receives Significant Equity Compensation Package

REGENXBIO Inc. Director Argeris N. Karabelas was granted 7,768 restricted stock units and 39,815 stock options as part of his compensation, aligning his interests with the company's long-term performance.

Summary

• REGENXBIO Inc. Director Argeris N. Karabelas was granted 7,768 shares of common stock in the form of Restricted Stock Units (RSUs) on May 30, 2025.
• These RSUs will fully vest on May 1, 2026, contingent upon his continuous service to the company.
• Additionally, Mr. Karabelas received 39,815 stock options with an exercise price of $8.85 per share, also on May 30, 2025.
• These stock options will vest in 12 equal monthly installments starting from May 30, 2025, subject to his continuous service, and have an expiration date of May 30, 2035.
• Following these transactions, Mr. Karabelas beneficially owns 19,054 shares of common stock and 39,815 stock options.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is generally a positive sign of alignment and retention. It does not contain negative financial news or operational setbacks. The grants are part of standard corporate governance and compensation practices.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with the long-term performance and shareholder value creation of REGENXBIO Inc.
• Equity compensation is a standard practice for retaining and incentivizing key management and board members.

Negatives

• The issuance of new equity awards could lead to minor dilution for existing shareholders upon vesting and exercise, though this is typical for compensation plans.

Risks

• The vesting of both RSUs and stock options is contingent upon the continuous service of the recipient, meaning the awards could be forfeited if the director's service ceases before vesting.

Future Outlook

The equity grants are designed to incentivize the director's continued service and align his interests with the company's long-term strategic goals, with vesting periods extending into 2026 and option expiration in 2035.

Management Comments

• The document is a standard SEC Form 4 filing and does not contain direct quotes or paraphrased statements from company management, other than the signature of the attorney-in-fact.

Industry Context

Equity compensation, including RSUs and stock options, is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate highly skilled executives and board members. This practice helps align the interests of insiders with those of shareholders, particularly in industries with long development cycles and significant R&D investments like biotech.

Comparison to Industry Standards

• The grant of RSUs and stock options to a director is a standard form of executive and board compensation across the biotechnology and broader corporate landscape.
• While specific values vary by company size, stage, and individual contribution, the structure of time-based vesting for RSUs and monthly vesting for options with a 10-year term is consistent with typical industry compensation packages aimed at long-term retention and performance alignment.
• No specific comparable companies or projects are mentioned in this filing to allow for a direct quantitative comparison.

Corporate Governance

Related Party Transactions

• The grant of equity compensation to a director (Argeris N. Karabelas) constitutes a related party transaction, as it involves a transaction between the company and an individual holding a significant position within the company.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares upon RSU vesting and option exercise, but also benefit from increased alignment of director's interests with long-term company performance.
• Director (Argeris N. Karabelas): Receives significant equity compensation, incentivizing continued service and providing a direct stake in the company's success.

Next Steps

• The RSUs are scheduled to vest on May 1, 2026, subject to continuous service.
• The stock options will continue to vest in 12 equal monthly installments following May 30, 2025, subject to continuous service.

Key Dates

Keywords

REGENXBIO, RGNX, SEC Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, RSU, Stock Options, Director Compensation, Beneficial Ownership, Biotechnology, Pharmaceuticals